Kazem R, Messinis L E, Fowler P, Groome N P, Knight P G, Templeton A A
Department of Obstetrics and Gynaecology, University of Aberdeen, UK.
Hum Reprod. 1996 Dec;11(12):2585-90. doi: 10.1093/oxfordjournals.humrep.a019174.
Mifepristone interrupts folliculogenesis in women but the mechanism is not clear. Previous studies have investigated the effect of this compound on gonadotrophin secretion and have provided conflicting results. To study further the effect of mifepristone on basal and gonadotrophin-releasing hormone (GnRH)-induced gonadotrophin secretion, 12 normally ovulating women were investigated during two consecutive menstrual cycles, comprising an untreated cycle (control) and a cycle treated with mifepristone. All women were treated with mifepristone on days 2-8 at the dose of 100 mg (group 1, eight women) or 10 mg per day (group 2, six women). Two women were treated with both regimens in two different cycles. On day 8 of both cycles, the women received two GnRH pulses of 10 micrograms each 2 h apart. Blood samples in relation to the first GnRH pulse were taken at-15, 0, 30, 60, 120, 150, 180 and 240 min. In group 1, the increase in luteinizing hormone (delta LH) in response to GnRH was significantly attenuated from 30 to 180 min, while the increase in follicle stimulating hormone (delta FSH) was attenuated only in response to the second GnRH pulse. No significant decrease in delta LH and delta FSH response to GnRH was seen during treatment with the 10 mg dose (group 2). In group 1, serum oestradiol and inhibin-A concentrations after day 8 were lower than in the control cycles and the LH peak was postponed by 7 days on average. Basal LH values increased significantly on day 8 in both groups, while FSH values did not change significantly compared with the control cycles. A significant increase in serum progesterone and cortisol values occurred during the treatment only in group 1. Mid-luteal values of inhibin-A were significantly lower in cycles treated with 100 mg mifepristone than in the control cycles. We conclude that the disruption of folliculogenesis by mifepristone cannot be explained by a decrease in basal FSH concentrations during the critical period of follicle recruitment and selection. It is possible that mifepristone exerts its effect at the level of the ovary. It is also suggested that progesterone during the follicular phase of the cycle may participate in the control of the self-priming action of GnRH on the pituitary.
米非司酮可干扰女性的卵泡生成,但其机制尚不清楚。以往的研究调查了该化合物对促性腺激素分泌的影响,结果相互矛盾。为了进一步研究米非司酮对基础促性腺激素及促性腺激素释放激素(GnRH)诱导的促性腺激素分泌的影响,在两个连续的月经周期中对12名正常排卵的女性进行了研究,包括一个未治疗周期(对照)和一个用米非司酮治疗的周期。所有女性在第2 - 8天接受米非司酮治疗,剂量为100毫克(第1组,8名女性)或每天10毫克(第2组,6名女性)。两名女性在两个不同周期接受了两种治疗方案。在两个周期的第8天,这些女性每隔2小时接受两次10微克的GnRH脉冲。在第一次GnRH脉冲相关的时间点,即-15、0、30、60、120、150、180和240分钟采集血样。在第1组中,GnRH刺激后促黄体生成素(ΔLH)的升高在30至180分钟显著减弱,而促卵泡生成素(ΔFSH)的升高仅在对第二次GnRH脉冲时减弱。在10毫克剂量治疗期间(第2组),未观察到ΔLH和ΔFSH对GnRH反应的显著降低。在第1组中,第8天后血清雌二醇和抑制素A浓度低于对照周期,LH峰平均推迟7天。两组第8天基础LH值均显著升高,而FSH值与对照周期相比无显著变化。仅在第1组治疗期间血清孕酮和皮质醇值显著升高。用100毫克米非司酮治疗的周期中抑制素A的黄体中期值显著低于对照周期。我们得出结论,米非司酮对卵泡生成的干扰不能用卵泡募集和选择关键期基础FSH浓度的降低来解释。米非司酮可能在卵巢水平发挥作用。还表明,月经周期卵泡期的孕酮可能参与GnRH对垂体自启动作用的控制。